By vgreene, 18 May, 2020 VTE prophylaxis per usual standard of care, per WHO, NIH; consider VTE if rapid deterioration or sudden perfusion loss1,5
By vgreene, 18 May, 2020 VTE prophylaxis per usual standard of care, per NIH; consider VTE if rapid deterioration or sudden perfusion loss8
By vgreene, 18 May, 2020 Meds for COVID-19: No drugs are FDA-approved for COVID-19; see epocrates resource: Consensus Guidelines for COVID-19 Drug Therapies
By vgreene, 18 May, 2020 Association of Treatment With Hydroxychloroquine or Azithromycin With In Hospital Mortality in Patients With COVID 19 in New York State
By vgreene, 18 May, 2020 Study considerations retrospective N 1 438 random sampling imbalanced baseline characteristics treatment bias varied dosing and duration possible missed readmissions ADRs at any time during hospital visit potentially prior to tx
By vgreene, 18 May, 2020 Abnormal ECG more common in HCQ+AZ (27%) and HCQ (27%) vs AZ (16%) and no tx (14%), but no difference in adjusted analysis; more pts w/ cardiac arrest in HCQ+AZ (16%) and HCQ (14%) vs AZ (6%) and no tx (7%)
By vgreene, 18 May, 2020 Unadjusted analysis for in-hospital mortality (overall 20%), HCQ+AZ 26%, HCQ 20%, AZ 10%, no tx 13%; adjusted analysis for in-hospital mortality showed no differences when comparing pts w/ no tx to each drug group, and when comparing HCQ vs AZ
By vgreene, 18 May, 2020 Retrospective multicenter cohort study; 1,438 randomly selected hospitalized pts (median age 63y) in NYC metro area w/ confirmed COVID-19 treated w/ HCQ (n=271) or AZ (n=211) alone, HCQ+AZ (n=735), or no tx (n=221); significant imbalances btwn groups, inc